Cancer diagnostics company, Pacific Edge, has announced that the Local Coverage Determination (LCD) for genetic testing in oncology, which includes Cxbladder tests, has become effective in the US, resulting in the halt of Medicare coverage for these tests.
The company said it would now focus on seeking coverage through Medicare appeals and reconsideration requests.
Pacific Edge's chief executive, Dr Peter Meintjes, expressed disappointment over the loss of coverage and the impact on Medicare patients and urologists.
He said the company had planned for this possibility and would continue to generate further evidence while pursuing the reconsideration pathway.
Pacific Edge's Cxbladder tests are used for the diagnosis and prognosis of bladder cancer.
See more
